Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C

Journal of Medical Virology

Volumn 85, Issue 2, 2013, Pages 250-260

  Kohjima, Motoyuki ^a   Enjoji, Munechika ^a,b   Yoshimoto, Tsuyoshi ^a   Yada, Ryoko ^a   Fujino, Tatsuya ^a   Aoyagi, Yoko ^a   Fukushima, Nobuyoshi ^a   Fukuizumi, Kunitaka ^a   Harada, Naohiko ^a   Yada, Masayoshi ^c   Kato, Masaki ^c   Kotoh, Kazuhiro ^c   Nakashima, Manabu ^b   Sakamoto, Naoya ^d   Tanaka, Yasuhito ^e   Nakamuta, Makoto ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cholesterol; Hepatitis C virus; IL28B; Replicon system

Indexed keywords

ICOSAPENTAENOIC ACID ETHYL ESTER; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PITAVASTATIN; RIBAVIRIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REPLICON; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; QUINOLINES; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84871070984     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23464     Document Type: Article

References (55)

1. Aghemo A, Rumi MG, Colombo M. 2009. Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 7:925-935.
2. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380.
3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50:361-368.
4. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429.
5. Alter HJ. 2005. HCV natural history: The retrospective and prospective in perspective. J Hepatol 43:550-552.
6. Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. 2011. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol 83:1048-1057.
7. Backus LI, Boothroyd DB, Phillips BR, Mole LA. 2007. Prediction of response of US veterans to treatment for the hepatitis C virus. Hepatology 46:37-47.
8. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M. 2008. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103:1383-1389.
9. Baril M, Racine ME, Penin F, Lamarre D. 2009. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 83:1299-1311.
10. Bortoletto G, Scribano L, Realdon S, Marcolongo M, Mirandola S, Franceschini L, Bonisegna S, Noventa F, Plebani M, Martines D, Alberti A. 2010. Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 17:475-480.
11. Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J, Meurs EF. 2005. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 79:3969-3978.
12. Chang KO, George DW. 2007. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 81:9633-9640.
13. Ekisioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, Liu C. 2011. Characterization of HCV interactions with toll-like receptors and RIG-I in liver cells. ProS ONE 6:e21186.
14. El-Serag HB, Johnson ML, Hachem C, Morgana RO. 2009. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136:1601-1608.
15. El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, Hotta H. 2012. Polymorphism of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology 55:1-11.
16. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. 2010. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408.
17. Fujino T, Nakamuta M, Yada R, Aoyagi Y, Yasutake K, Kohjima M, Fukuizumi K, Yoshimoto T, Harada N, Yada M, Kato M, Kotoh K, Taketomi A, Maehara Y, Nakashima M, Enjoji M. 2010. Expression profile of lipid metabolism-associated genes in HCV-infected human liver. Hepatol Res 40:923-929.
18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
19. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. 2010. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52:864-874.
20. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K. 2011. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60:261-267.
21. Huang H, Chen Y, Ye J. 2007. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 104:18666-18670.
22. Ikeda M, Kato N. 2007. Life style-related diseases of the digestive system: Cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 105:145-150.
23. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. 2006. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117-125.
24. Jouan L, Melançon P, Rodrigue-Gervais IG, Raymond VA, Selliah S, Boucher G, Bilodeau M, Grandvaux N, Lamarre D. 2010. Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease. J Hepatol 52:167-175.
25. Kanwal F, Hoang T, Spiegel BM, Elsen S. 2007. Predictions of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors. Hepatology 46:1741-1749.
26. Kapadia SB, Chisari FV. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102:2561-2566.
27. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Nakashima M, Nakamuta M. 2009. The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol Anim 45:6-9.
28. Kumada T, Toyoda H, Honda T, Kuzuya T, Katano Y, Nakano I, Goto H. 2006. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 49:112-118.
29. Kushner DB, Lindenbach BD, Grdzelishvili VZ, Noueiry AO, Paul SM, Ahlquist P. 2003. Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc Natl Acad Sci USA 100:15764-15769.
30. Lemon SM. 2010. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 285:22741-22747.
31. Leu GZ, Lin TY, Hsu JTA. 2004. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 318:275-280.
32. Liu HM, Gale M. 2010. Hepatitis C virus evasion from RIG-I-dependent hepatic innate immunity. Gastroenterol Res Pract 2010:548390.
33. Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, Kanai F, Imazeki F, Yokosuka O. 2009. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 44:872-877.
34. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S. 2010. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol 16:184-192.
35. Nakamuta M, Yada R, Fujino T, Yada M, Higuchi N, Tanaka M, Miyazaki M, Kohjima M, Kato M, Yoshimoto T, Harada N, Taketomi A, Maehara Y, Koga M, Nishinakagawa T, Nakashima M, Kotoh K, Enjoji M. 2009. Changes in the expression of cholesterol metabolism-associated genes in the HCV-infected liver: A novel target for therapy? Int J Mol Med 24:825-828.
36. Nakamuta M, Fujino T, Yada R, Aoyagi Y, Yasutake K, Kohjima M, Fukuizumi K, Yoshimoto T, Harada N, Yada M, Kato M, Kotoh K, Taketomi A, Maehara Y, Nakashima M, Enjoji M. 2011. Expression profiles of genes associated with viral entry in HCV-infected human liver. J Med Virol 83:921-927.
37. Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18:281-285.
38. Scholtes C, Diaz O, Icard V, Kaul A, Bartenschlager R, Lotteau V, André P. 2008. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol 48:192-199.
39. Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2009. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52:43-48.
40. Shiffman ML. 2002. Retreatment of patients with chronic hepatitis C. Hepatology 36:S128-S134.
41. Shimada M, Yoshida S, Masuzaki R, Schuppan D. 2012. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study. J Hepatol 56:299-300.
42. Simons K, Ehehalt R. 2002. Cholesterol, lipid lafts, and disease. J Clin Invest 110:597-603.
43. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
44. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Nakamura Y, Miyakawa Y, Kumada H. 2011. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53:415-421.
45. Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. 2007. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology 50:439-446.
46. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, Kakinuma S, Watanabe M. 2004. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J Infect Dis 189:1129-1139.
47. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
48. Tasaka M, Sakamoto N, Itakura Y, Nakagawa M, Itsui Y, Sekine-Osajima Y, Nishimura-Sakurai Y, Chen CH, Yoneyama M, Fujita T, Wakita T, Maekawa S, Enomoto N, Watanabe M. 2007. Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. J Gen Virol 88:3323-3333.
49. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. 2011. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53:389-395.
50. Toyoda M, Kitaoka A, Machida K, Nishinakagawa T, Yada R, Kohjima M, Kato M, Kotoh K, Sakamoto N, Shiota G, Nakamuta M, Nakashima M, Enjoji M. 2011. Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. Int J Mol Med 27:619-624.
51. Wang C, Gale M, Keller BC, Huang H, Brown MS, Goldstein JL, Ye J. 2005. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 18:425-434.
52. Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T. 2011. Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. J Gen Virol 92:2082-2087.
53. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. 2007. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 51:2016-2027.
54. Ye J, Wang C, Sumpter R, Brown MS, Goldstein JL, Gale M, Jr. 2003. Disruption of hepatitis C virus replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 100:15865-15870.
55. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. 2003. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4:602-608.